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Background: In neuroblastoma, the presence of distant metastases is associated with a poor 
prognosis.  
Aim: To assess the relationship between the findings on 123I-MIBG scan and outcome in 
patients with neuroblastoma at the Red Cross War Memorial Children’s Hospital 
(RCWMCH). 
Methods: A single observer reviewed the 123I-MIBG scans and clinical data of patients who 
had a histologically confirmed diagnosis of neuroblastoma and a baseline 123I-MIBG scan and 
at least one follow up scan after chemotherapy cycles 4 or 7 between January 2001 and May 
2015. Follow up extended to June 2016. Disease burden was assessed using the Curie scoring 
(CS) method.  
Results: Thirty four stage 4 patients were included in the analysis. Twenty nine (85%) were 
older than 12 months, with a median age at diagnosis of 32.5 months (range 6 – 93 months). 
62% of primary tumours were located in the adrenal gland and half were NMYC amplified. 
Twenty (59%) patients died, 90% of deaths occurring in patients older than 12 months. No 
deaths were recorded in the 13 months after recruitment ended. The baseline CS did not 
predict outcome (alive or dead) or duration of survival. Patients with CS >2 (n = 5) on the 
cycle 4 scan had a median survival of 19.5 months compared with 29 months for those with a 
score ≤ 2 (n = 17, p = 0.88). Patients with a CS > 2 on the cycle 7 scan (n = 7) had a median 
survival of 28 months compared with 35 months for those with CS ≤ 2 (n = 14, p = 0.93). 
There was no relationship between the magnitude of the decrease in CS between the baseline 
and post cycle 4 or 7 scans and outcome.  
Conclusion: In these 34 high risk patients, the baseline CS and CS at cycle 4 or cycle 7 were 
not significantly indicative of survival. This is similar to other studies that did not find the 
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 1.0 RESEARCH PROTOCOL 
This research protocol was submitted to and approved by the Faculty of Health Sciences, 
University of Cape Town before commencement of the study. 
Title of study: 
Relationship between 123I-metaiodobenzylguanidine (123I-MIBG) imaging findings at 
diagnosis and outcome in patients with neuroblastoma at the Red Cross War Memorial 
Children’s Hospital 
1.1 Background  
Neuroblastomas are common solid tumours of childhood.1 The presence or absence of 
metastases is a major factor influencing prognosis.2, 4, 8, 15, 16 Bone scintigraphy permits 
visualisation of the entire skeleton and is valuable for assessing bone metastases. However, 
because the bone scan assesses the metabolic changes in bone due to the neuroblastoma 
tumour, disease as assessed on the bone scan is not specific. On one hand, uptake on bone 
scan may be due to new infiltration of bone by neuroblastoma. Conversely, the uptake may 
be related to enhanced bone metabolic activity occurring in areas of bone healing following 
treatment. The bone scan is unable to differentiate these two pathologic processes and is 
therefore not useful for disease follow up or in assessing response to therapy.2 The 
radiopharmaceutical 123I-MIBG is the nuclear medicine agent of choice for staging and 
assessment of therapy response.2, 3 While the overall stage of neuroblastoma is seldom 
different whether bone scan or 123I-MIBG imaging is used, there may be a difference when 
assessment is done on a lesion-by-lesion basis.2 At the Red Cross War Memorial Children’s 
Hospital (RCWMCH), patients with neuroblastoma are currently assessed using both bone 
scan and 123I-MIBG imaging at staging and 123I-MIBG is used for follow up of patients. 
Nearly three decades ago, Daubenton and co-workers4 reported on the relationship between 
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bone scan findings and prognosis in neuroblastoma patients at the RCWMCH. They showed 
that abnormal bone scan findings at diagnosis were associated with a poor outcome. The 
presence of 123I-MIBG avid disease at diagnosis and follow up have been reported to be 
predictive of poor outcome16, 19 but to the best of our knowledge, there has been no review of 
the relationship between the findings on 123I-MIBG and outcome in the South African setting. 
The aim of the current study is to assess the relationship between the results of 123I-MIBG 
scan and outcome in patients with neuroblastoma at RCWMCH. 
1.2 Literature review 
Neuroblastomas arise from neuro-ectodermal tissue. Studies from different parts of the world 
report varying incidence rates for neuroblastoma; in Europe and North America, they account 
for about 8% of malignant tumors in childhood1 while a rate of approximately 3% has been 
reported from Mexico.5 Stones and co-workers6, working in South Africa reported that 
neuroblastoma accounted for 5.8% of tumours in their paediatric cohort.  
The disease can occur anywhere along the sympathetic chain from the base of the skull to the 
pelvis. Regarding the site of the primary tumour, 35% are found in the adrenal gland with 
20% in the posterior mediastinum. About 35% originate in the paraspinal ganglia, with 5% 
each in the pelvic and neck regions.21 The clinical presentation is largely dependent on the 
location of the primary tumour in the sympathetic nervous system and the presence or 
absence of metastases. The clinical presentation of the disease is variable but patients with 
metastatic disease are usually quite ill and usually have pain as a prominent symptom. 
Patients may also present with cord compression, skin bruising or proptosis. In some cases, 
affected children present with paraneoplastic phenomena such as intermittent hypertension 
and diarrhoea. Occasionally, the diagnosis is suspected prenatally following the identification 
of a mass.21 Neuroblastoma commonly spreads to cortical bone and bone marrow; up to 70% 
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of patients have dissemination of disease into bone and/ or bone marrow at presentation.7 
Less frequently, there is spread to liver, skin, and lungs.  
A primary tumour is not detected in up to 10% of children with disseminated neuroblastoma 
and in those who present with paraneoplastic syndromes.7 Whether a primary tumour is 
detected or not does not impact the prognosis of the disease if metastases is already present. 
However, a primary tumour when detected may be resected if it is surgically possible to do so 
as this can result in an improvement in patient symptoms albeit without an impact on overall 
survival.  
The International Neuroblastoma Staging System2 (INSS) is utilised for disease staging and is 




Table 1: International Neuroblastoma Staging System2 
Stage  Description  
1 Localised tumour with complete gross excision with or without 
microscopic residual disease; contralateral and representative 
ipsilateral regional lymph nodes negative for disease (nodes attached 
to and removed with primary tumour may be positive)  
2A Localised tumour with incomplete gross resection; ipsilateral and 
contralateral nodes negative for tumour  
2B Localised tumour with complete or incomplete resection; positive 
ipsilateral (non-adherent) nodes; contralateral nodes are negative for 
tumour 
3 Unresectable lateral tumour that crosses the midline* with or without 
regional lymph node involvement; or localised unilateral tumour with 
contralateral lymph node involvement; or midline tumour with 
bilateral extension by infiltration or lymph node involvement 
4S Patients younger than 12 months of age with localised tumour (as 
defined for stages 1, 2A or 2B) and metastases confined to liver, skin, 
and/ or bone marrow  
4 Tumour with distant metastases not fulfilling stage 4S 
*midline is defined as the vertebral column. Tumours originating on one side and crossing the midline must 
infiltrate to or beyond the opposite side of the vertebral column. 
Age at diagnosis and disease stage are important prognostic factors in neuroblastoma; older 
age at diagnosis and more advanced disease are associated with poor outcome.8, 9, 10 Patients 
with stage 1, 2 or 4S tend to have a good prognosis with overall survival of patients with 
5 
stage 1 and 2 disease ranging from 80 – 100%.8, 9 In children under age 1 year with stage 4 
disease and children older than 12 – 18 months with stage 3 or stage 4 disease, the prognosis 
is poor.4, 10, 11  
Screening for neuroblastoma can be done using measurement of urine catecholamines, 
routine physical examinations including abdominal palpation or abdominal ultrasound. At the 
present time, general screening for neuroblastoma is not recommended.33 However, Powell et 
al12 reported on the differences in diagnosis of neuroblastoma in children resident in Europe. 
Their study included details of the manner of presentation (whether the symptoms of 
neuroblastoma were present at diagnosis or whether the disease was an incidental finding 
arising during a routine paediatric examination or during investigation of an unrelated 
disorder such as cryptorchidism). While the children resident in Germany, Austria and UK 
had information on the manner of presentation, such information was not available for 
children from France. They found that in countries with routine childhood health screening 
programmes (Germany and Austria) children were diagnosed with neuroblastoma at an 
earlier age and with early stage disease. The proportion of early stage disease (stages 1, 2 and 
3) was higher in Germany, Austria and France than in the United Kingdom (UK) where no
screening programme existed. The proportion with stage 4 disease was higher in the UK 
(61.5% versus 40%) and UK children aged 1-2 years, had significantly more stage 4 disease 
than their counterparts in France or Germany.12  
There are differences in the epidemiology of neuroblastoma in developed and developing 
countries. In Mexico, a developing country, affected children present at an older age, with 
more advanced disease and with unfavourable histology.13 The median age at presentation in 
the Mexican study was 27 months compared with 14.5 – 21.6 months in a European study.12 
In a previous report from RCWMCH, 4 only 6 of 30 patients with neuroblastoma were 
younger than 1 year of age. Further, stage 4 disease was more predominant in Mexico than in 
6 
some European countries (60% versus 40% respectively). 12, 13 Approximately 30% of 
patients in France and Germany were reported to have either stages 1, 2 or 4S disease12, this 
is in contrast to Mexico where the proportion of children with similar disease stages was only 
20%.13 These differences among children at the time of presentation are largely responsible 
for the observed differences in disease outcomes between developed and developing 
countries.12, 13
Imaging and urine biochemistry for catecholamines or their metabolites (vanillylmandelic 
acid, homovanillic acid) are usual investigations done prior to surgery or biopsy. Other non-
specific markers include thrombocytosis, raised ferritin, neuron-specific enolase, and lactate 
dehydrogenase. Magnetic resonance imaging (MRI), computed tomography (CT), bone 
scintigraphy and MIBG scanning are useful imaging modalities for disease staging in 
neuroblastoma.21  
MRI and CT are anatomic imaging modalities useful for determining size of primary tumour, 
extent of regional disease (regional invasion, vascular encasement, lymphadenopathy, and 
calcification) and to detect distant metastases; MRI is especially helpful for evaluating 
disease extension to the spinal canal.29 Although both CT and MRI can detect cortical bone 
metastases in neuroblastoma, the detection is limited to the area included in the scan. With no 
exposure to radiation, MRI has an advantage but this is offset by the usual requirement for a 
general anaesthetic in the majority of patients affected with neuroblastoma. The Radiology 
Diagnostic Oncology group29 compared the accuracies of CT, MRI and bone scintigraphy for 
staging in neuroblastoma. In that study, all patients had a CT of the chest or abdomen and 
pelvis (depending on the site of the primary tumour) using a fourth generation scanner. MRI 
was performed using a 1.5T scanner; the included field of view was dependent of the site of 
the primary tumour: all patients had an MRI of the bone marrow (pelvis, proximal femora 
and spine) and the chest or abdomen and pelvis; the pelvis was routinely included in the 
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abdominal examination while the thoracic or lumbar spine was studied depending on the site 
of the primary tumour. The authors of the study reported CT and MRI to have sensitivities of 
43% and 83% respectively for detecting stage 4 disease; the specificities were 97% and 88% 
respectively. Computed tomography has the advantage of being more widely available and is 
useful for delineating vascular encasement by tumour in the process providing information 
about surgical resectability of the primary tumour.  
The radiopharmaceuticals 123I-MIBG and 131I-MIBG are selectively taken up by tumour cells 
of sympatho-adrenal origin and are known to provide a sensitive method for detecting and 
evaluating metastases in neuroblastoma.14, 15, 16 Due to the lower radiation dose and optimal 
imaging characteristics, 123I-MIBG (rather than131I-MIBG) is the preferred 
radiopharmaceutical for imaging of neuroblastoma.3 Imaging with MIBG serves as a useful 
means of assessing disease extent and severity at diagnosis, thus aiding the choice of 
therapy.2 MIBG imaging is also utilised to ascertain the response to therapy, and to detect 
residual or recurrent disease during follow up.2, 3 In neuroblastoma, 123I-MIBG imaging is 
reported to have sensitivity of 88 – 93% and specificity of 83 – 92%.32 MRI as a modality has 
a lower specificity than MIBG imaging for detecting metastatic disease in neuroblastoma.30 
Much of the advantage of MIBG imaging over CT or MRI derives from the fact that it allows 
functional assessment to help distinguish viable metabolically active disease from post 
therapy changes.30 A combination of MIBG imaging with MRI has been shown to improve 
the sensitivity and specificity of disease detection in neuroblastoma: values of 99% and 95% 
respectively have been reported.30 
The presence of extensive MIBG avid disease on the initial staging scan at diagnosis or 
during treatment usually predicts poor outcome.16, 19 A positive MIBG scan after induction 
chemotherapy or just before myeloablative therapy portends poor prognosis.14, 17 Kusher et 
al31 reported on the sensitivities of various surveillance studies for detecting relapse in high 
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risk neuroblastoma. They found 123I-MIBG to be superior with a detection rate of 82% 
compared to 64%, 34% and 36% for 131I-MIBG scan, bone marrow histology and bone scan 
respectively. This led them to conclude that 123I-MIBG scan is essential for valid estimation 
of duration of relapse free survival of patients with neuroblastoma. 
While some children present with only one or two foci of MIBG avid metastases, others 
present with more extensive disease at diagnosis. Semi quantitative scoring systems have 
been recommended by the International Neuroblastoma Risk Group Task Force for the 
assessment of extent and severity of MIBG avid disease at diagnosis and for evaluating 
treatment response in neuroblastoma.15 The Curie method, the first developed scoring system, 
is easy to use24 and is the most widely used for assessing disease burden at diagnosis and 
evaluating response to therapy. This scoring system divides the skeleton into 9 segments and 
utilises a 4-point scoring system to grade uptake. A modification, the modified Curie scoring 
system, which incorporates a tenth segment for soft tissue uptake16 has also been used 
extensively. The modified Curie scoring method has good reproducibility with reported inter-
observer concordance rate of 92%16. Messina and colleagues,18 found an inter-observer 
concordance rate of approximately 95% among users of this modified Curie method. Disease 
burden as assessed by the Curie or modified Curie score at diagnosis or during induction 
chemotherapy has been found to correlate with overall response, and with event free 
survival.16, 18, 19 Lewington and co-workers25 published the SIOPEN method in 2009. The 
SIOPEN method divides the skeleton into 12 segments; the extent of involvement of each 
segment is scored on a scale of 0 – 6 giving a maximum extension score of 72. Soft tissue 
involvement is assessed separately in the SIOPEN method. The SIOPEN method was 
reported to have a concordance of 95% when tested in a blinded review by 6 Nuclear 
Medicine Physicians.25 The Frappaz scoring system divides the body into 7 segments, 
measures an intensity score for each affected site using a 4 point scale and has a maximum 
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score of 21. The overall semi quantitative Frappaz score has good inter observer concordance 
rate (over 80%)26 but is less reliable than the modified Curie score for assessing treatment 
response partly because it ignores soft tissue involvement in its assessment of disease 
extent.15, 16  
Suc et al27 performed a retrospective review of the pre-treatment 123I MIBG scans of 86 
patients older than 1 year of age with neuroblastoma. They assessed disease burden using a 
scoring system that ranged from 1 to 7 and divided the patients into two groups: group A with 
score < 4 and group B with score > 4. They reported that children less than 2 years of age and 
with pre-treatment score < 4 had a higher remission rate following induction chemotherapy. 
A score > 4 was associated with a 6.9 fold increased risk of not attaining complete remission 
(95% CI 2.4 – 19.6) after 4 cycles of induction chemotherapy.  
The presence of a Curie score > 2 after induction therapy has been reported to be associated 
with extremely poor survival (15.4% 3-year event free survival).19 Similar findings were 
reported by Katzenstein and colleagues.28 Furthermore, Yanik et al19 reported that patients 
with MYCN-amplified disease had little benefit from stem cell transplantation and 
subsequent consolidation therapy if they had an Curie score > 0 after induction therapy. 
Messina and colleagues18 used the modified Curie system to assess disease burden in a group 
of 49 patients with relapsed or refractory neuroblastoma who were treated with 131I-MIBG. 
They showed that patients with a lower relative extension score (defined as the absolute post 
therapy score divided by the absolute pre-therapy score) were more likely to attain complete 
(CR) or partial response (PR) to therapy. The median relative score for patients with CR or 
PR was 0.3 compared to 0.98 for those with no response (NR) or progressive disease (PD); 
this was statistically significant. Further analysis revealed that 68% of patients with a relative 
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extension score ≤ 0.5 had treatment response while only 11% of those with relative extension 
score ≥ 0.5 had a treatment response.18 
The relationship between the pattern of uptake and disease burden on the MIBG scan and 
outcome of neuroblastoma has been reported recently.20 In that study, MIBG avid lesions 
were categorised as focal or diffuse. Lesions in body segments which showed margins that 
were clearly distinguishable from background were classified as focal. Lesions with no 
clearly defined margins were categorised as diffuse. According to the authors of that study,20 
a focal metastatic pattern is associated with better event free and overall survival in patients 
with N-myc amplified tumours. As the burden of disease is essential in guiding the choice of 
treatment, an accurate assessment of MIBG uptake and localisation in neuroblastoma tumours 
is essential both during the initial staging and on follow up.  
For neuroblastoma, limited local disease is amenable to surgery and this will lead to complete 
removal of the tumour. On the other hand, metastatic disease or disease not surgically 
resectable will require prolonged chemotherapy or irradiation and bone marrow 
transplantation may benefit some children with this presentation.21, 22 If post therapy scan 
indicates absent metastases, then surgery may be done to remove the primary. At the end of 
treatment, the absence of MIBG uptake on the post treatment scan in conjunction with absent 
disease on other imaging modalities (such as computed tomography, magnetic resonance 
imaging and 18F – FDG positron emission tomography) is an indicator of good treatment 
response. On the other hand, the presence of MIBG uptake in previous known sites or in new 
areas indicates non response or a recurrence of disease. It is therefore essential that disease 





1.3 Study questions 
i. Does disease burden as assessed using the modified Curie score on the pre-treatment 
123I-MIBG scan predict outcome in patients with neuroblastoma? 
ii. Does the form of uptake (focal versus diffuse) on the pre-treatment 123I-MIBG scan 
predict outcome in patients with neuroblastoma? 
iii. Does disease burden as assessed using the modified Curie score on the post treatment 
123I-MIBG scan predict outcome in patients with neuroblastoma? 
iv. Does the form of uptake on the post treatment scan predict outcome in patients with 
neuroblastoma? 
v. What is the effect of an initial 123I-MIBG scan on the interpretation of the post 
treatment scan? 
vi. What are the relationships between the modified Curie score, pattern of uptake and 
age, N-myc status, surgical clearance of disease, bone marrow infiltration at end of 
treatment and outcome? 
1.4 Purpose of the study 
This study is being conducted in partial fulfilment of the requirements for the award of an 
MMed degree in Nuclear Medicine by the University of Cape Town. It will provide 
information on the impact of 123I-MIBG on the management of neuroblastoma patients at 




1.5.1 Study design 
This will be a retrospective review of 123I-MIBG scans in conjunction with laboratory, 
clinical and other available imaging data of patients with neuroblastoma who were treated at 
the Oncology unit of RCWMCH between January 2001 and May 2015. 
1.5.2 Characteristics of the study population 
The population for the study will comprise all patients with histologically confirmed 
neuroblastoma. Neuroblastoma patients who have a baseline/ pre-treatment 123I-MIBG scan 
and at least one post-treatment scan will be included in the study. The baseline 123I-MIBG 
scan should have been done prior to initiation of chemotherapy. Post treatment scan should 
have been done at the end of chemotherapy.  
1.5.3 Exclusion criteria 
i. Poor technical quality images
ii. Patients with no pre-treatment MIBG scan
1.5.4 Research procedures and data collection methods/ method for evaluating the 123I-
MIBG scans 
The raw data of 123I-MIBG scans of all patients with neuroblastoma will be retrieved from the 
electronic archives of the Nuclear Medicine department of the Red Cross Hospital. The 123I-
MIBG scans will be anonymised by the Supervisor of this dissertation so that the single 
observer is unaware of the patient name or folder number or the date on which the images 
were acquired or the report issued. On the first occasion, the single observer will also not be 
aware of which images are baseline/ pre-treatment or post treatment/ follow up scans. All the 
anonymised images will be retrieved and re-processed by the observer. The location of any 
lesion, the body segments involved, and the extent of involvement in a segment will be 
13 
recorded according to the modified Curie 4-point scoring system as shown in figure 1. The 
level of diagnostic certainty and intensity of uptake of involved segments will be recorded 
using the schema shown in table 2 and table 3 respectively. In addition, the form/ pattern of 
the uptake seen on the MIBG scan will be assessed and characterised as focal or diffuse using 
the method described by Bleeker et al.20 Briefly, lesions in each segment on the scans which 
show margins that are clearly distinguishable from background will be classified as focal. 
Lesions with no clearly defined margins will be categorised as diffuse. The number of focal 
and diffuse lesions in each segment will be counted and recorded.  
At least 2 weeks after all scans have been reviewed, the single interpreter will review all the 
images again. He will be given a matched list of pre-treatment and post treatment scans by the 
supervisor. The raw data of the matched scans will be retrieved from the archives, reprocessed 
and findings recorded. Again, the location of any lesion, number of segments involved, and the 
extent of involvement of a segment will be assessed and recorded according to the scoring 
scheme as described earlier and shown in figure 1 and the level of diagnostic certainty and 
intensity of uptake of involved segments will also be recorded using the schema shown in table 
2 and table 3 respectively. The burden of disease will be assessed on the pre-treatment and 
post-treatment scans using the modified Curie 4-point scoring.  The modified Curie score on 
the pre- and post- treatment scans will be computed and recorded. Again, the number of focal 
and diffuse lesions on each scan will be counted and recorded.  
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Table 2: Scores for certainty of lesion detection and localisation34 
Score Certainty Description 
0 Unknown Don’t know 
1 Possible Might know 
2 Probable Have a good idea 
3 Definite Sure 
 
Table 3: Scores for intensity of uptake18 
Score  Description  
0 No sites of uptake 
1 Doubtful uptake 
2 Obvious but mild uptake 





Figure 1: Scoring system dividing the skeleton into 9 compartments. A 10th compartment (not 
shown) will be used for soft tissue lesions.15 
 
Schema for scoring for each segment  
0 no uptake/ no foci  
1 one focal lesion  
2 more than one focal lesion  
3 diffuse involvement (≥ 50% of segment 
involved) 
 
Soft-tissue lesions will be scored as follows: 
0, no MIBG involvement; 1, one MIBG-
avid soft-tissue lesion present; 2, more than 
one MIBG-avid soft-tissue lesion present; 
and 3, MIBG avidity in a soft-tissue lesion 
that occupies 50% of the chest or abdomen 
 
*Maximum attainable score is 30 
*Focal uptake: uptake with clearly defined 
margins 
*Diffuse uptake: uptake with margins 





Once all the images have been reviewed and findings recorded as per the data sheets, the 
observer will be given a list of the folder number associated with each set of images. The 
oncology folders of all participants will be retrieved from the archives of the Oncology 
department of the hospital. Patient age, gender, date of diagnosis of neuroblastoma, site of 
primary tumour, disease stage, histopathology, and bone marrow biopsy results will be 
recorded on data sheet 3. The urine catecholamine results, N-myc status, routine 
haematology, serum LDH results and details of chemotherapy will also be abstracted on to 
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data sheet 3. The clinical outcome/ events and date of each event, date of last clinic visit/ last 
known contact and duration of follow up will be noted. To ensure that the observer is blinded 
to the clinical information of patients (other than the diagnosis of neuroblastoma) during the 
review of the images, the abstraction of data from the clinic folders will only be done after 
the evaluation of all the MIBG images. 
1.5.5 Data analysis 
Data will be entered in to a database.  
i. Intra observer agreement of the effect of the pre-treatment scan on the post-treatment 
review will be assessed using the kappa coefficient  
ii. Data will be analysed for extent of disease as assessed by a semi-quantitative score on 
the pre- and post-treatment scans.  
iii. Analysis will be made on per lesion and per patient bases for level of certainty of 
lesion detection/ localisation and extent of segment involvement on the baseline and 
follow up MIBG scans.  
iv. The numbers of patients with exclusively focal (focal), focal more than/ equal to 
diffuse (focal ≥ diffuse), more diffuse than focal (diffuse > focal), and exclusively 
diffuse (diffuse) lesions during the image evaluation sessions will be analysed. 
v. Data will be analysed for assessment of relationship between the semi quantitative 
scores on the pre- and post-treatment scans and outcome/ survival of patients.  
vi. The relationship between the form of the uptake (focal or diffuse) and outcome will 
be assessed.  
vii. Comparison will also be made between the scores and other clinical and imaging 
results.  
viii. The relationship between the N-myc status and number of involved body segments 
per patient will be assessed. 
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Survival will be assessed using the Kaplan-Meier life table method. Event free survival will 
be calculated as the time from diagnosis to the first event (relapse, progression, death) or last 
examination/ last known contact if no event occurred. Overall survival will be calculated as 
the time from diagnosis to death or last examination. Differences in overall survival and 
event free survival between different groups will be assessed using the log-rank test. 
1.6 Limitations  
i. This will be a retrospective study 
ii. A single observer will be involved in interpreting the scans due to constraints of time 
1.7 Description of risks and benefits 
The images were acquired in accordance with guidelines on MIBG scintigraphy in children 
issued by the European Association of Nuclear Medicine.3 There was no deviation from these 
guidelines for the purpose of this study. As the images to be evaluated are those which have 
already been acquired and are in the archives of the Nuclear Medicine department at the 
hospital, there will be no additional risk to the study subjects as no new imaging will be done 
in the course of this study.  
1.8 Informed consent process 
The study is retrospective and shall involve analysis of examinations which were recorded as 
part of the routine management of patients with neuroblastoma at the RCWMCH and which 
were used in the management of the children. 
1.9 Privacy and confidentiality 
No patient names will be used in the study or during preparation of the final study report. 
Paper based records will be kept in a secure location and be accessible to only persons 
involved in the study. All patient related data will be anonymised at all times to ensure 




1.10 Emergency care and insurance for research-related injuries 
The retrospective nature of the study means that no study subject will be exposed to any 
injury during the period.  
1.11 What happens at the end of a study? 
The findings of the study will be submitted as a dissertation to the University of Cape Town 
in partial fulfilment for the award of the MMed degree in Nuclear Medicine. A final study 
report will be submitted to the Departments of Nuclear Medicine and Oncology at the 
hospital. The findings of the study will also be disseminated through presentations at 
workshops and publication in a scientific journal. 
1.12 Funding  
All the data to be reviewed in the current study have been previously acquired as part of the 
routine care of patients with neuroblastoma in the hospital. No funding will be required for 
the acquisition of any new data. There will be no costs to the hospital during this study. All 
costs emanating from purchase of stationary, photocopying and printing will be catered for by 




1. Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev. 2010; 36:277-285
2. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for
neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol.1993; 11:
1466–1477
3. Bombardieri E, Giammarile F, Aktolun C, et al. 131I/123I-Metaiodobenzylguanidine
(mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol
Imaging. 2010; 37:2436–2446
4. Daubenton JD, Fisher RM, Karabus CD, Mann MD. The relationship between
prognosis and scintigraphic evidence of bone metastases in neuroblastoma. Cancer
1987; 59(9):1586-1589
5. Fajardo-Gutiérrez A, Juárez-Ocaña S, González-Miranda G, et al. Incidence of cancer
in children residing in ten jurisdictions of the Mexican Republic: importance of the
Cancer registry (a population-based study). BMC Cancer 2007, 7:68
6. Stones DK, De Bruin GP, Esterhuizen TM, Stefan DC.  Childhood cancer survival
rates in two South African units. S Afr Med J 2014;104(7):501-4
7. Berthold F, Brandeis W, Lampert F. Neuroblastoma: Diagnostic advances and
therapeutic results in 370 patients. Monogr Paediatr 1986;18: 206-223
8. De Bernardi B, Rogers D, Carli M, et al: Localized neuroblastoma. Surgical and
pathologic staging. Cancer 1987;60: 1066-1072
9. Castleberry RP, Kun LE, Shuster JJ, et al. Radiotherapy improves the outlook for
patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma. J
Clin Oncol 1991; 9:789-795
20 
 
10. Schmidt ML, Lal A, Seeger RC, et al: Favorable prognosis for patients 12 to 18 
months of age with stage 4 nonamplified MYCN neuroblastoma: A Children’s Cancer 
Group study. J Clin Oncol 2005; 23:6474-6480 
11. Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk 
Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009; 27: 
298–303  
12. Powell JE, Estève J, Mann JR, et al, on behalf of SENSE. Neuroblastoma in Europe: 
differences in the pattern of disease in the UK. Lancet 1998; 352: 682–87 
13. Juárez-Ocaña S, Palma-Padilla V, González-Miranda G, et al. Epidemiological and 
some clinical characteristics of neuroblastoma in Mexican children (1996–2005). 
BMC Cancer 2009, 9:266 
14. Perel Y, Conway J, Kletzel M, et al. Clinical impact and prognostic value of 
metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. J 
Pediatr Hematol Oncol 1999; 21(1): 13–18 
15. Matthay KK, Shulkin B, Ladenstein R, et al. Criteria for evaluation of disease extent 
by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the 
International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer. 2010; 
102(9): 1319-1326 
16. Matthay KK, Edeline V, Lumbroso J, et al. Correlation of early metastatic response 
by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free 
survival in stage IV neuroblastoma. J Clin Oncol. 2003; 21: 2486–2491 
17. Ladenstein R, Philip T, Lasset C, et al. Multivariate analysis of risk factors in stage 4 
neuroblastoma patients over the age of one year treated with megatherapy and stem-
21 
cell transplantation: a report from the European Bone Marrow Transplantation Solid 
Tumor Registry. J Clin Oncol. 1998; 16: 953– 965  
18. Messina JA, Cheng SC, Franc BL, et al. Evaluation of semi-quantitative scoring
system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed
neuroblastoma. Pediatr Blood Cancer. 2006; 47(7): 865–874
19. Yanik GA, Parisi MT, Shulkin BL, et al. Semiquantitative mIBG scoring as a
Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the
Children’s Oncology Group. J Nucl Med 2013; 54:541–548
20. Bleeker G, van Eck-Smit BL, Zwinderman KH, et al. MIBG scans in patients with
stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN
amplification and in MYCN-amplified tumours correlates with a better prognosis. Eur
J Nuc Med Mol Imaging. 2015;42:222-230
21. Hallett A, Traunecker H. A review and update on neuroblastoma. Paediatrics and
Child Health. 2011; 22(3):103-107
22. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma
with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation,
and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med.1999;
341(16):1165–1173
23. World Medical Association Declaration of Helsinki 2002. Ethical Principles for
Medical Research Involving Human Subjects.
http://wma.net/en/30publications/10policies/b3/17c.pdf. accessed on 4 June 2015
22 
 
24. Ady N, Zucker JM, Asselain B, et al. A new 123I-MIBG whole body scan scoring 
method - Application to the prediction of the response of metastases to induction 
chemotherapy in stage IV neuroblastoma. Eur J Cancer. 1995;31A(2):256–261 
25. Lewington V, Bar Sever Z, Lynch T, et al. Development of a new, semi-quantitative 
I-123 mIBG reporting method in high risk neuroblastoma. J Nucl Med. 2009;50(Suppl 
2):1379  
26. Frappaz D, Bonneu A, Chauvot P, et al. Metaiodobenzylguanidine assessment of 
metastatic neuroblastoma: Observer dependency and chemosensitivity evaluation. The 
SFOP Group. Med Pediatr Oncol. 2000;34:237–241 
27. Suc A, Lumbroso J, Rubie H, et al. Metastatic neuroblastoma in children older than 
one year: Prognostic significance of the initial metaiodobenzylguanidine scan and 
proposal for a scoring system. Cancer 1996;77(4):805–811  
28. Katzenstein HM, Cohn S, Shore R, et al. Scintigraphic response by 123I-
metaiodobenzylguanidine scan correlates with event-free survival in high-risk 
neuroblastoma. J Clin Oncol. 2004;22:3909-3915 
29. Siegel MJ, Ishwaran H, Fletcher BD, et al. Staging of neuroblastoma at imaging: 
Report of the Radiology Diagnostic Oncology Group. Radiology. 2002;223(1):168-
175 
30. Pfluger T, Schmied C, Porn U, et al. Integrated imaging using MRI and 123I 
metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the 
diagnosis of pediatric neuroblastoma. Am J Roentgenol 2003; 181:1115 – 1124  
31. Kushner BH, Kramer K, Modak S, Cheung NV. Sensitivity of surveillance studies for 
detecting asymptomatic and unsuspected relapse of high risk neuroblastoma. J Clin 
Oncol. 2009; 27: 1041- 1046 
23 
 
32. Vik TA, Pfluger T, Kadota R, et al. 123I-mIBG scintigraphy in patients with known or 
suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood 
Cancer. 2009; 52(7):784-790 
33. Schilling FH, Spix C, Berthold F, et al. Neuroblastoma screening at one year of age. 
N Engl J Med. 2002; 346(14):1047-53 
34. Yunusa GH. Assessment of the impact of the application of Single Photon Emission 
Computerized Tomography and SPECT-CT on lesion categorization. Dissertation 






2.0  PUBLICATION READY MANUSCRIPT 
(See appendix IV for Journal of Pediatric Hematology and Oncology author guidelines) 
Title: Relationship between 123I-metaiodobenzylguanidine (123I-MIBG) imaging findings and 
outcome in patients with neuroblastoma at the Red Cross War Memorial Children’s Hospital 
Authors: 
Yaw Ampem Amoako1, FWACP, Anita Brink2, MMed, Ann Van Eyssen3, FCPaed, Mike 
Mann2, PhD 
1Nuclear Medicine Division, Groote Schuur Hospital & Red Cross War Memorial Children’s 
Hospital and University of Cape Town 
2Nuclear Medicine Division, Red Cross War Memorial Children’s Hospital and University of 
Cape Town 
3Paediatric Oncology Service, Red Cross War Memorial Children’s Hospital and University 
of Cape Town 
Address for correspondence: 
Dr Yaw Ampem Amoako 
A3.62 Nuclear Medicine Division, Medical Imaging Department 
Red Cross War Memorial Children’s Hospital 
Klipfontein Road, Rondebosch  
Cape Town 7700 
Tel: +27846189726/ +27 21 6585367 
Fax: +27216585367 
Email: yamoako2002@yahoo.co.uk  
 




To assess the relationship between the findings on 123I-MIBG scan and outcome in patients 
with neuroblastoma at the Red Cross War Memorial Children’s Hospital (RCWMCH), a 
single observer reviewed the 123I-MIBG scans and clinical data of patients who had a 
histologically confirmed diagnosis of neuroblastoma and a baseline 123I-MIBG scan and at 
least one follow up scan after chemotherapy cycles 4 or 7 between January 2001 and May 
2015. Follow up extended to June 2016. Disease burden was assessed using the Curie scoring 
(CS) method.   Thirty four stage 4 patients were included. Twenty (59%) patients died, 90% 
of deaths occurring in patients older than 12 months. No deaths were recorded in the 13 
months after recruitment ended. The baseline CS did not predict outcome (alive or dead) or 
duration of survival. The 5 patients with CS > 2 (n = 5) on the cycle 4 scan had a median 
survival of 19.5 months compared with 29 months for the 17 with a score ≤ 2 (p = 0.88). The 
7 children with a CS > 2 on the cycle 7 scan had a median survival of 28 months compared 
with 35 months for the 14 with CS ≤ 2 (p = 0.93). There was no relationship between the 
magnitude of the decrease in CS between the baseline and post cycle 4 or 7 scans and 
outcome. In these 34 high risk patients, the baseline CS and CS at cycle 4 or cycle 7 did not 
predict survival.  




2.2 Main manuscript  
Introduction  
Neuroblastomas are common solid tumours of childhood that arise from neuro-ectodermal 
tissue.1 In South Africa, neuroblastoma accounts for 5.8% of paediatric tumours.2 Poor 
prognostic factors in neuroblastoma include age at diagnosis, presence of metastases, NMYC 
amplification and an unfavourable histology.3, 4  
The radiopharmaceutical 123I-MIBG is the nuclear medicine imaging agent of choice in the 
assessment for presence of metastases and therapy response.5 In view of reports of 
discordance between results of 123I-MIBG and bone scan findings in some cases of 
neuroblastoma, 6- 8 we assess patients with neuroblastoma using both bone scan and 
123I-MIBG imaging at staging and 123I-MIBG imaging is used during follow up. 
The semi-quantitative Curie scoring system was developed to assess disease burden in bone 
and bone marrow. The Curie score (CS) is reported to have good intra- and inter-observer 
concordance9-10 and is useful in assessing patients after treatment.11-12 It divides the body into 
9 skeletal segments (head, cervico-thoracic spine, ribs/ sternum/ scapula, lumbosacral spine, 
pelvis, upper arms, forearm/ hands, upper legs and lower legs/ feet). Lesions in each skeletal 
segment are scored on a scale of 0 to 3 as: 0, no uptake in segment; 1, one MIBG avid lesion 
present; 2, more than 1 MIBG avid lesion present; 3, MIBG uptake involving ≥ 50% of a 
particular segment. Patients without disease or with low CS post treatment have a good 
quality of life and good event free survival. Yanik et al12 reported that in stage 4 
neuroblastoma, patients with a post therapy CS > 2 (more than 2 distinct lesions in skeletal 
segments) after induction chemotherapy have a poorer outcome compared to those with score 
≤ 2. A relative Curie score (calculated as the ratio of post therapy CS to pre-therapy CS), has 
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been used to identify patients with refractory neuroblastoma who are likely to benefit from 
131I-MIBG therapy.10 
Nearly three decades ago, Daubenton and co-workers13 reported on the relationship between 
bone scan findings and prognosis in neuroblastoma patients at the Red Cross War Memorial 
Children’s Hospital (RCWMCH). They showed that abnormal bone scan findings at 
diagnosis were associated with a poor outcome. The current study aimed to assess the 
relationship between the results of 123I-MIBG scan and outcome in patients with 
neuroblastoma at RCWMCH. 
Materials and methods  
Patient population 
We performed a retrospective review of 123I-MIBG scans and clinical, laboratory and other 
available imaging data of patients with neuroblastoma who presented to the RCWMCH 
between January 2001 and May 2015. The images of patients with histologically confirmed 
neuroblastoma who had a baseline 123I-MIBG scan before the start of any chemotherapy and 
at least one subsequent scan during or after completion of treatment were retrieved from the 
electronic archives of the Nuclear Medicine department of the hospital. The follow up 
extended till June 2016 to allow for a follow up period of at least 13 months from 
presentation.  
Treatment protocol for high risk neuroblastoma at RCWMCH 
In most cases, high risk neuroblastoma patients receive 7 cycles of conventional therapy 
comprising vincristine, cisplatin, etoposide, cyclophosphamide (i.e. OPEC) alternating with 
vincristine, carboplatin, etoposide, cyclophosphamide (i.e. OJEC) every 21 days. Patients are 
reviewed with imaging and bone marrow biopsy. If there is no disseminated disease, that is 
bone and bone marrow disease have resolved after 4 cycles of first line chemotherapy, 
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surgery is performed to debulk (as much as possible) or remove the primary tumour. Post-
surgery, external beam radiotherapy is administered to the residual tumour or surgical bed. A 
further 3 cycles of chemotherapy are given followed by 6 months of cis-retinoic acid (CRA). 
If there is still disseminated disease (on MIBG imaging or bone marrow biopsy) after 4 
cycles, chemotherapy is continued for a further 3 cycles. If the review after 7 cycles shows no 
bone or bone marrow disease, the patient undergoes surgery followed by radiotherapy of 
surgical bed or residual tumour and 6 months of CRA. However, if there is still disseminated 
disease after 7 cycles of OPEC/ OJEC, then palliative treatment with cyclophosphamide, 
adriamycin, vincristine (CADO) is undertaken. Surgical resection of primary tumour is 
performed only if there is a response to CADO.  
Alternatively, patients older than 18 months with NMYC amplified tumours who have 
medical insurance may receive cisplatinum, adriamycin, etoposide, cyclophosphamide and 
vincristine (CAPE-O) as first line chemotherapy. A small proportion of patients opt for 
CADO as their preferred first line chemotherapy. 
123I-MIBG scanning 
All 123I-MIBG scans were acquired in accordance with the Guidelines on MIBG scintigraphy 
in children issued by the European Association of Nuclear Medicine (EANM). 5, 14 
Administered doses of 123I-MIBG were in accordance with EANM paediatric dosage 
guidelines.15-16 Whole body and static images were recorded 24 hours after injection of 
123I-MIBG (iThemba LABS, Old Faure Road, Faure, Cape Town, SA) using a Phillips Axis 
dual head camera (previously known as Picker and then Marconi) fitted with a low energy 
high resolution collimator. Whole body images were acquired using a matrix size of 1024 x 
256 while static images were acquired using a 256 x 256 matrix for a duration of 300s. An 
acquisition zoom as appropriate for age of the child was used (maximum zoom applied was 
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2). Baseline scans were recorded before the start of any chemotherapy and subsequent scans 
were performed after 4 or 7 cycles or both of chemotherapy. 
Interpretation of 123I-MIBG scans 
The raw data of the 123I-MIBG scans of the patients were retrieved from the electronic 
archives of the Nuclear Medicine department of the Red Cross War Memorial Children’s 
Hospital. The  123I-MIBG scans were anonymised by 1AB so that the single observer 2YA 
was unaware of the patient’s name and folder number or the date on which each set of images 
were acquired. In addition, the single observer also was blinded to the clinical information of 
patients other than the diagnosis of neuroblastoma. Each set of images were processed and 
reviewed twice on a HERMES (version V1.0, 2005, Hermes Medical Systems, Sweden) 
physicians’ workstation. On the first occasion, the single observer was also not aware of 
whether images were baseline, cycle 4 or cycle 7 scans. All the anonymised images were 
retrieved and re-processed. The location of each lesion, the body segment involved, and the 
extent of involvement in each segment were recorded according to the Curie 4-point scoring 
system9, 10. A modified Curie score (MCS) in addition to having 9 skeletal segments, includes 
a tenth segment for soft tissue involvement.  Lesions in soft-tissue were scored as follows: 0, 
no MIBG uptake in soft tissue; 1, one MIBG-avid soft-tissue lesion present; 2, more than one 
MIBG-avid soft-tissue lesion present; and 3, MIBG avidity in a soft-tissue lesion that 
occupies 50% of the chest or abdomen/ pelvis. Each patient’s score was calculated as the sum 
of the individual scores of all involved segments. All scans were scored using the curie and 
the modified curie score. In addition, the uptake seen in bone on the MIBG scan was assessed 
and characterised as focal or diffuse using the criteria described by Bleeker et al.17 Lesions 
identified as focal were clearly distinguishable from background. Lesions with no clearly 
                                                        
1 AB was supervisor for MMed dissertation 
2 YA was the MMed candidate 
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defined margins were categorised as diffuse. The number of focal and diffuse lesions in each 
skeletal segment was recorded. The intensity of uptake and level of diagnostic certainty of 
lesions were recorded.  
Three weeks after the first review, a second review of all the images was performed on 
matched pre- and post-treatment scans. The raw data of the anonymised matched scans were 
again retrieved from the electronic archives, reprocessed and findings recorded. The location 
of any lesion, number of segments involved, and the extent of involvement of a segment were 
assessed and recorded and the level of lesion certainty and intensity of uptake of involved 
segments were recorded using the same criteria utilised during the first review.  
Review of clinical data 
After all images had been reviewed twice, the anonymisation code was opened and the 
clinical information of patients was retrieved from the archived folders of the Oncology 
department of the hospital. Patient age, gender, date of diagnosis of neuroblastoma, site of 
primary tumour, disease stage, histopathology, and bone marrow biopsy results were 
recorded. The urine catecholamine results, NMYC status, routine haematology, serum 
ferritin, serum lactate dehydrogenase (LDH) results and details of chemotherapy were also 
abstracted. Disease staging was done in accordance with the International Neuroblastoma 
Staging System criteria18. The clinical outcome/ events and date of each event, date of last 
clinic visit/ last known contact and duration of follow up were noted.  
Ethical considerations 
The study was approved by the Human Research Ethics Committee of the University of Cape 





The data was analysed in two parts. The image review data set was analysed to determine if 
the interpretation of the cycle 4 and 7 scans changed when they were viewed in conjunction 
with the baseline scans. The number of lesions in the different skeletal and soft tissue 
segments when the cycle 4 and cycle 7 scans were viewed alone and when the cycle 4 and 
cycle 7 scans were viewed in conjunction with the baseline scan were compared for any 
possible changes. The second part of the analysis involved assessment of clinical data for any 
relationships with the MIBG scan findings. 
Clinical data are presented as frequencies and percentages. Overall survival was defined as 
the time from diagnosis till death or last examination. Survival was assessed using the 
Kaplan-Meier life table method. Differences in overall survival between different groups 
were assessed using the log-rank test. Statistical analyses were performed using R statistical 
package (version 3.2.3; The R Foundation for Statistical Computing) and Microsoft Office 
2013 Excel.  
Results  
Clinical characteristics of study participants 
Fifty seven (57) patients had at least two MIBG scans. Twelve patients were initially 
excluded; 3 patients because their clinic folders could not be traced and there was therefore 
no clinical data and 9 because they had stage 1, 2 or 3 disease leaving 45 patients with stage 4 
disease. A further 11 patients with stage 4 disease were excluded from the analysis because 1 
had no baseline scan and 10 because their follow up scans were performed at times other than 
after chemotherapy cycles 4 or 7. Thus, 34 patients with stage 4 disease were included in the 
analysis. The clinical and pathologic characteristics of the study participants are presented in 
Table 1. No patient had stage 4S disease. Twenty nine (85%) were older than 12 months and 
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the median age at diagnosis was 32.5 months (range 6 – 93 months). The adrenal gland was 
the most common site of the primary tumours and 50% of tumours had NMYC amplification. 
Twenty eight (82%) patients were treated with OPEC/ OJEC chemotherapy. No deaths 
occurred in the 13 months after recruitment ended. 
Timing of 123I-MIBG scans 
All the patients included in this study had a baseline MIBG scan before the start of 
chemotherapy. Of the 34 patients, 22 had scans acquired after chemotherapy cycle 4 (cycle 4 
scans) and 21 had scans after cycle 7 (cycle 7 scans).  Nine patients had cycle 4 and cycle 7 
scans.   
In 8 of the 12 patients who did not have a cycle 4 scan, the scan was not performed because 
the 123I-MIBG production plant was closed for maintenance. In 3, the scan was not performed 
because the bone marrow biopsy was normal while in 1 patient, there was no clear reason 
recorded.  
Thirteen patients had no scans at cycle 7. In 6 of these patients, the scans were not performed 
because the 123I-MIBG production plant was shut down for maintenance. Four patients did 
not have the scan performed because the cycle 4 scans were normal and bone marrow 
biopsies did not show any infiltration. In 1 patient, the post therapy bone marrow biopsy done 
after cycle 7 was normal and in 2 patients, the reason for the non-acquisition of the cycle 7 
scan was not clear.  
Effect of baseline scan on interpretation of cycle 4 and cycle 7 scans 
Skeletal lesions were most frequently seen in the lower limbs on both the cycle 4 and cycle 7 
scans. The forearm/ hands had the least number of lesions. 
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In the 22 patients who had cycle 4 scans, there were a total of 71 lesions (53 skeletal and 18 
soft tissue lesions) in the 10 body segments when the cycle 4 scan was viewed without the 
baseline scan. Sixty six lesions (53 skeletal and 13 soft tissue lesions) were counted when the 
post treatment scan was viewed in conjunction with the baseline scan (details in 
supplementary table S1). There was no change in the assessment of skeletal lesions in the 
head, cervico-thoracic, lumbosacral, upper arms, forearm/ hands, thighs and lower legs 
segments. Two patients with lesions in ribs/ sternum/ scapula segment (one with 2 lesions 
and other with 1 lesion) on the cycle 4 scan were downgraded (classified as having no 
lesions) when the cycle 4 scan was viewed in conjunction with the baseline scan.  One patient 
was upgraded to have 2 lesions in the pelvis (when the post cycle 4 scan was viewed alone, 
only a single lesion was seen in the pelvis).  
For the 21 patients who had cycle 7 scans, there was no change in the number of skeletal 
lesions counted when the scan was viewed alone or in conjunction with the baseline scan 
(supplementary table S2) but in 2 patients there was a change in the skeletal segments 
involved. There was no change in the assessment of skeletal lesions in the head, upper arms, 
forearms/ hands, pelvis, thighs and lower legs segments. Upgrading (patients re-classified as 
having lesions in a skeletal segment when the post cycle 7 and baseline scans were viewed 
together) occurred in 2 patients: 1 in the lumbosacral segment and 1 in the cervico-thoracic 
segment. Downgrading (patients re-classified as having no lesions in a skeletal segment when 
the post cycle 7 and baseline cans were viewed together) occurred in 2 patients for lesions in 
the ribs/ sternum/ scapula region. 
The overall effect of the baseline scan on the interpretation of the follow up scan was that in 
19 of 22 patients (86%) with cycle 4 and 17 of 21 patients (81%) with cycle 7 scans, the 
interpretation was unchanged when the follow up scan was viewed alone or in conjunction 
with the baseline scan. The certainty of lesion detection and the grading of intensity of lesions 
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were enhanced when the follow up scan was viewed together with the baseline scan. As 
expected, there was a very close correlation between the Curie and modified Curie scores (r = 
0.99). All scores referred to subsequently in this paper are Curie scores.  
Outcome of stage 4 neuroblastoma patients 
Twenty (59%) patients died and 14 were alive when follow up for this study ended. Ninety 
percent of deaths occurred in patients older than 12 months. The median age at diagnosis for 
alive patients was 21.5 months (range 6 – 93) vs 37.5 months (range 6 – 72) for those who 
died (Kruskal Wallis H = 1.03, p = 0.31). Thirty two patients had NMYC results available. Of 
the 17 patients with NMYC amplified tumours, 11 died and 6 were alive. Seven patients with 
NMYC not amplified tumours died: one was diagnosed at age 17 months and the other 6 
were ≥ 36 months at diagnosis, 4 patients with NMYC not amplified disease had poorly 
differentiated tumours and 4 had the primary tumour located in the adrenal gland.  
The median interval from diagnosis to death was 12 months (range 6 – 123 months). For 
alive patients, the median interval from diagnosis to the last recorded follow up for the study 
was 26.5 months (range 14 – 71 months). 
There was one treatment related death. This patient had an NMYC amplified primary tumour 
in the abdomen and died 6 months after diagnosis from disseminated intravascular 
coagulation 48 hours post-surgical resection of the primary tumour. The cycle 4 scan had a 
CS of 1.  
When the patient data was examined, it was noted that all 9 patients with a diagnosis date 
before March 2010 had died. All 14 alive patients were diagnosed after March 2010 while 11 
of the 25 patients diagnosed after March 2010 died (supplementary figure 1). We were unable 
to find a reason for this observation despite a review of the clinical notes and treatment 
protocols. The median overall survival of the 14 alive patients was 26.5 months (range 14 - 
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71) compared to 11 months (range 6 - 45) for the patients diagnosed after March 2010 who
died. 
Characteristics/ outcome of patients with cycle 4 scans 
Ten of 22 (45%) patients with cycle 4 scans died. Nine (90%) of deaths occurred in patients 
older than 12 months. The median age at diagnosis for patients in this category was 28.5 
months (range 6 – 93). For alive patients, the median age at diagnosis was 28 months (range 
6 - 93) compared to 30 months (range 6 – 52) for those who died (Kruskal Wallis H = 3.84, p 
= 0.82). The patients with NMYC not amplified tumours who died were diagnosed at age ≥ 
17 months. Nine alive patients had well differentiated tumours compared to 4 in the group 
who died. Of the alive patients, 5 had no uptake in a skeletal segment while 7 had skeletal 
disease on the post cycle 4 scan. The clinical and pathologic characteristics of patients with 
follow up scans at cycle 4 who died or remained alive are presented in table 2. 
Characteristics and outcome of patients with cycle 7 scans 
Thirteen of 21 (62%) of patients with cycle 7 scans died. The median age at diagnosis for 
patients with cycle 7 scans was 39 months (range 6 – 93). The median age at diagnosis for 
alive patients was 12.5 months (range 6 – 93) vs 44 months (range 7 – 72) for patients who 
died (Kruskal Wallis H = 2.31, p = 0.13). Twelve of 13 deaths were in patients who were 
diagnosed at age ≥ 20 months. The remaining child, diagnosed at age 7 months had a CS = 0 
after 7 cycles but died 123 months after diagnosis following disease relapse. Five of the 8 
alive patients were age ≤ 13 months at diagnosis. Four of 8 alive patients had disease in a 
skeletal segment and 4 had no skeletal uptake on the cycle 7 scan. 
Seven of the patients who died had poorly differentiated tumours compared to 2 in the alive 
group. Six patients who died had NMYC amplified tumours compared to 2 alive patients. The 
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clinical and pathologic characteristics of patients with follow up scans at cycle 7 who died or 
remained alive are presented in table 3. 
Curie score (CS) and outcome for patients with cycle 4 scans 
Baseline Curie score (CS) and outcome for patients with cycle 4 scans 
Five patients did not have any uptake in a skeletal segment on the baseline scan; however, all 
5 patients had bone marrow infiltration on biopsy and evidence of cortical bone involvement 
on the bone scan performed at diagnosis. The baseline CS did not predict outcome (alive or 
dead) or duration of survival. The survival of the 8 patients with baseline CS ≤ 2 was not 
statistically different from the 14 with CS > 2 (median overall survival median overall 29 vs 
13 months, p = 0.64).  
Post cycle 4 CS and outcome 
Patients with post cycle 4 CS > 2 (n = 5) had median overall survival of 19.5 months 
compared to 29 months for those with CS ≤ 2 (n = 17), p = 0.88. At 29 months, the 
proportion of those alive with post cycle 4 CS ≤ 2 was more than thrice the proportion of 
those with CS > 2 (fig 1).  
Curie score (CS) and outcome for patients with cycle 7 scans 
Baseline Curie score (CS) and outcome for patients with cycle 7 scans 
Five patients in this group did not have any uptake in a skeletal segment on the baseline scan.  
However, all 5 patients had evidence of cortical bone involvement on the bone scan and 3 
had bone marrow infiltration on biopsy performed at diagnosis. Again, the baseline CS did 
not predict outcome (alive or dead) or duration of survival. The survival of patients with 
baseline CS ≤ 2 (n = 6) was not significantly different from those with CS > 2 (n = 15). The 
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median overall survival was 23 months for patients with baseline CS ≤ 2 compared to 28 
months for those with CS > 2, p = 0.28.  
Post cycle 7 CS and outcome 
Patients with CS > 2 on the cycle 7 scan (n = 7) had median overall survival of 28 months 
compared with 35 months for those with CS ≤ 2 (n = 14), p = 0.93. At 45 months, the 
proportion of those alive with post cycle 7 CS ≤ 2 was more than thrice the proportion of 
those with CS > 2 (fig 2).  
CS and outcome in patients who were diagnosed after March 2010 
The predictive value of CS in patients diagnosed after March 2010 was analysed separately. 
The median OS for patients with CS ≤ 2 was 45 months compared to 19 months for those 
with CS > 2, p = 0.30.  
Change in baseline and cycle 4 Curie scores and survival/ tumour response 
A relative Curie score was calculated for each patient as the ratio of cycle 4 score to the 
baseline score. This relative CS was used as a measure of tumour response to treatment. The 
median survival for stage 4 neuroblastoma patients with less than 50% reduction in tumour 
burden from baseline (relative CS > 0.5, n = 8) was not statistically different from patients 
who had at least a 50% reduction (relative CS ≤ 0.5, n = 14) in tumour burden (28 months vs 
29 months, p = 0.93. At 29 months, the proportion of patients alive with relative CS ≤ 0.5 
was more than thrice the proportion of those with relative CS > 0.5. There was no difference 




Change in baseline and cycle 7 Curie scores and survival/ tumour response 
The relative score at cycle 7 was calculated as the ratio of the cycle 7 score to the baseline 
score. The 14 patients with relative CS ≤ 0.5 at cycle 7 had a median survival of 28 months 
compared to 93 months for the 7 patients with relative score > 0.5, p = 0.71 (fig 3). There was 
no difference in the survival of patients with relative score ≤ 0.75 (n = 15) and those with 
score > 0.75 (n = 6). 
Alive and dead patients had decreases in CS on the follow up scan at cycle 4 or 7. There was 
no relationship between the magnitude of decrease in CS and outcome (supplementary 
figures 2a and 2b).  
Form of uptake on baseline scan and survival  
The patients with no abnormal uptake on the baseline scan were excluded from the analysis 
of pattern of uptake and survival as there was no pattern of uptake to classify. For the survival 
analysis, patients with focal uptake (F) on the baseline scan were considered as one category. 
All patients with more focal than diffuse (FD), diffuse (D) and more diffuse than focal (DF) 
uptake baseline were also grouped as one category. The survival of patients with F uptake 
was compared to those with FD or D or DF uptake.  
Form of uptake on baseline scan and survival for patients with cycle 4 scans 
While 2 patients with focal uptake died, there were 8 deaths in patients with FD or D or DF 
uptake. There was no difference in survival between patients with focal uptake (n = 6) and 
those with FD or D or DF uptake (n = 16), median survival 26 months vs 28 months, p = 
0.44. Even when the pattern of uptake was categorised as F or FD and D or DF, there was 
still no difference in survival with respect to the pattern of uptake. 
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We did not have sufficient patient numbers to enable assessment of the relationship between 
form of uptake and survival in patients with NYMC amplified tumours who had cycle 4 
scans.  
Form of uptake on baseline scan and survival for patients with cycle 7 scans 
Four patients with focal uptake died with 9 deaths occurring in patients with FD or D or DF 
uptake. There was no difference in survival between patients with focal uptake (n = 7) and 
those with FD or D or DF uptake (n = 14), median survival 123 months vs 28 months, p = 
0.48. When the pattern of uptake was classified as F or FD and D or DF, there was still no 
difference in survival with respect to the pattern of uptake. 
We did not have sufficient patient numbers to enable assessment of the relationship between 
form of uptake and survival in patients with NYMC amplified tumours who had cycle 7 
scans.  
Discussion  
To our knowledge, this is the first review of the relationship between 123I-MIBG imaging 
findings and outcome in a neuroblastoma series in South Africa. We found that there was no 
change in assessment of number of lesions in skeletal segments on the cycle 4 or cycle 7 
scans when viewed alone or together with baseline scan. This is in agreement with previous 
reports of good intra-observer concordance when the semi-quantitative Curie scoring is used 
in the evaluation of MIBG scans in patients with neuroblastoma.9-11 The major impact of 
viewing the matched cycle 4 or cycle 7 and baseline scans was that there was greater 
certainty of lesion detection. 
Eighteen of the 20 patients in our series who died were older than 12 months at diagnosis, 11 
of them had NMYC amplified tumours while only 6 patients with NMYC amplified tumours 
were alive. Nine patients who died had poorly differentiated tumours compared to 3 in the 
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alive group. This is similar to previous reports of older age at diagnosis, presence of NMYC 
amplification and poor tumour differentiation being associated with a worse prognosis in 
neuroblastoma.3- 4, 13 
We found that the baseline CS did not predict outcome in our cohort. This is similar to other 
reports that the pre-treatment score is not a predictor of prognosis.6, 12 Yanik and colleagues
reported that in patients with stage 4 neuroblastoma, there was no correlation between the 
pre-treatment CS and treatment outcome.12  In a study of 30 patients with stage 4 
neuroblastoma in the United States, Perel and colleagues6 found that the 2 year event free 
survival of patients with initial (pre-treatment) MIBG scores ≥ 10 was not different from 
those with score < 10 (27.8% ± 11.7 vs 59.2% ± 14.1%, p = 0.23).  
The Curie score after 4 or 7 cycles of chemotherapy did not predict outcome in our high risk 
neuroblastoma cohort. Previous studies have reported on the prognostic significance of semi-
quantitative score post therapy. Yanik and colleagues studied 280 patients with stage 4 
neuroblastoma who were on Children Oncology Group (COG) protocol A3973. MIBG scans 
were evaluated using the same criteria as in our study. They reported that patients with a 
Curie score > 2 (n = 52) had decreased event free survival (EFS) compared to those with 
Curie scores ≤ 2 (n = 185) after induction therapy with 3-year EFS of 15.4% ± 5.3% vs. 
44.9% ± 3.9%, p = 0.001).12 Additionally, they found that patients with ≥ 50% reduction in 
Curie score from diagnosis to after induction (n = 194) had a much better survival when 
compared to those with < 50% reduction (n = 43) (3-year EFS: 42.9% ± 3.8% vs. 17.3% ± 
5.9%, p = 0.001). In patients with relapsed neuroblastoma, those with relative scores (ratio of 
post therapy CS to pre-therapy CS) ≤ 0.5 are reportedly more likely to have a complete or 
partial response to 131I-MIBG therapy.10 Katzenstein et al20 studied the prognostic 
significance of MIBG scan scores in a group of 29 neuroblastoma patients with age at 
diagnosis > 18 months in Chicago. They used a scoring scheme that divided the skeleton into 
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10 segments (in contrast to our study, their study divided the head into 2 segments namely 
calvarium and base of the skull-face). They reported that the post induction scan predicted 
prognosis as MIBG score ≥ 3 after induction therapy was associated with a significantly 
worse event free survival. Although the pattern of our results is similar to previous reports by 
Yanik et al12 and Katzenstein et al,20 we did not find any statistically significant difference 
between the survival of patients with cycle 4 or cycle 7 CS > 2 and those with score ≤ 2.  
Patients with < 50% reduction in tumour burden from diagnosis to post treatment have been 
reported to have a worse event free survival when compared to those with ≥ 50% reduction.12 
In our series, the overall survival of these 2 groups was not significantly different. In the 
study by Perel et al,6 they reported that an abnormal post induction chemotherapy MIBG scan 
was associated with a poor outcome: all 5 patients with uptake on the post induction scan had 
disease relapse while 8 of 16 patients with normal post therapy scans were reported to be in 
progression-free remission. In contrast, Andrich et al did not find post therapy MIBG 
imaging findings to be predictive of prognosis.21 In that study, 8 out of 13 patients with stage 
4 disease and normal post therapy 131I-MIBG scans had disease relapse at one or more sites 
leading the authors to conclude that normalisation of MIBG scan after therapy was not a 
predictor of outcome.  
Residual MIBG avid disease on the post induction chemotherapy MIBG scan predicts poor 
outcome after allogenic stem cell transplant22 and relapse after high dose therapy with 
peripheral blood stem cell rescue, local radiotherapy, and cis-retinoic acid.20  
Bleeker et al17 reported that in patients with NMYC amplified tumours, those with focal 
lesions had a much better event free survival (EFS) and overall survival (OS) than those in 
the other metastatic groups (focal ≥ diffuse + diffuse > focal + diffuse) with 5-year EFS and 
5-year OS of 63 ± 24% vs. 21 ± 15%, p = 0.006 and 81 ± 20 % vs. 28 ± 17 %, p = 0.001
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respectively. In contrast, an exclusively focal pattern of uptake was not associated with a 
better overall survival in patients with NMYC amplified disease in the present study. The 
median age at diagnosis of patients in the study by Bleeker et al was similar to those in our 
cohort (34 months vs 32.5 months respectively); however that study included 84 patients with 
NMYC amplified disease (total number of study patients was 249) compared to 17 patients 
with NMYC amplified tumours in the present study. This difference may be responsible for 
the differences in our results.  
While the international recommendations regarding the use of 123I-MIBG in staging and 
response assessment of neuroblastoma are clear, there are challenges in the local South 
African (and probably entire African) setting that impact the use. 123I-MIBG is cyclotron 
produced and we rely on iThemba LABS for supply. For several months each year, the 
radiopharmaceutical is unavailable for use as the production plant is shut down for 
maintenance. Thus, some patients do not get MIBG imaging at staging while others do not 
get the follow up imaging. Several patients were excluded from this study because they did 
not have scans performed at baseline, or at cycle 4 and 7 as dictated by the treatment protocol 
at RCWMCH due to shutdown of the MIBG production plant. Other stage 4 patients were 
excluded from the analysis because the follow up scan was only performed after a substantial 
time interval, again due to production shutdown. This shutdown impacts patient management 
and also makes it more difficult to establish the beneficial value of MIBG imaging in 
neuroblastoma in our setting.  
Treatment costs for neuroblastoma are high and some specific decisions regarding treatment 
are impacted by whether or not the affected patient has medical insurance. For instance, 
colony stimulating factor (GCSF) support for patients who develop neutropenia and 




Limitations of study 
This was a retrospective study and may have had the biases usually associated with such 
study designs. However, we attempted to reduce the influence of bias by abstracting the 
clinical data only after all MIBG scans had been reviewed. Only a single observer was 
involved in the interpretation of the MIBG scans. Any bias on the part of the sole observer 
was ameliorated by anonymisation of the MIBG scans and allowing an interval of 3 weeks 
between the first and second image review sessions. The shutdown of MIBG production at 
iThemba LABS impacted the number of patients included in our study. Not all patients 
presenting with neuroblastoma to our institution were included in this study. Several patients 
with neuroblastoma who did not have follow up scans as dictated by protocol were excluded 
from the study. The small number of patients in our analysis may have precluded our ability 
to show differences in survival of the magnitude reported by Yanik et al.12 
This study conducted a review of MIBG scan findings and clinical data of stage 4 
neuroblastoma patients in South Africa. There was no change in the assessment of number of 
skeletal lesions on the follow up scan when viewed alone or in conjunction with baseline scan 
but the certainty of lesion detection and grading of lesion intensity was enhanced. Similar to 
previous reports, the baseline CS did not predict prognosis in stage 4 neuroblastoma. 
However, unlike other reports, the CS on the cycle 4 and cycle 7 scans did not also indicate 
prognosis in our cohort of high risk neuroblastoma patients. In addition, the magnitude of 
reduction in CS did not carry prognostic significance in our cohort. 
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Table 1: Clinical and pathologic characteristics of all neuroblastoma patients 
Characteristic Age at 
diagnosis 
(months) 

















<12 5 M 17 Abdomen 8 Present 17 Positive 31 Abnormal  28 Abnormal  7 OPEC/OJEC 28 
12-
24 
9 F 17 Adrenal 21 Absent 15 Negative 1 Normal 6 Normal 26 CAPE-O 5 




<12 2 M 11 Abdomen 6 Present 11 Positive 18 Abnormal 15 Abnormal 6 OPEC/OJEC 16 
12-
24 
5 F 9 Adrenal 11 Absent 7 Negative 1 Normal 5 Normal 13 CAPE-O 3 
>24 13 Thorax 1 NA 2 Not 
available 







<12 1 M 5 Abdomen 4 Present 7 Positive 9 Abnormal 7 Abnormal 2 OPEC/OJEC 11 
12-
24 
3 F 6 Adrenal 5 Absent 4 Negative 1 Normal 4 Normal  8 
>24 7 Thorax 0 NA 0 NA 1 NA 0 NA 1 
Pelvis 2 
Alive, n=14 <12 3 M 6 Abdomen 2 Present 6 Positive 13 Abnormal 13 Abnormal  1 OPEC/OJEC 12 
12-
24 
4 F 8 Adrenal 10 Absent 8 Negative 0 Normal 1 Normal 13 CAPE-O 2 
>24 7 Thorax 1 NA 0 NA 1 NA 0 NA 0 CADO 0 
Pelvis 1 
M=male, F=female, NA=not available 
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Table 2: Clinical and pathologic characteristics of neuroblastoma patients who had follow up scans at cycle 4 
Characteristic Age at 
diagnosis 
(months) 

















n = 22 
<12 3 M 11 Abdomen 4 Present 9 Positive 21 Abnormal  20 Abnormal  3 Poor 7 
12-
24 
6 F 11 Adrenal 16 Absent 12 Negative 0 Normal 2 Normal 18 Well 13 
>24 13 Thorax 1 NA 1 NA 1 NA 0 NA 1 NA 2 
Pelvis 1 
Dead, n = 10 <12 1 M 6 Abdomen 2 Present 5 Positive 9 Abnormal  8 Abnormal  2 Poor 4 
12-
24 
3 F 4 Adrenal 8 Absent 4 Negative 0 Normal 2 Normal 7 Well 4 
>24 6 Thorax 0 NA 1 NA 1 NA 0 NA 1 NA 2 
Pelvis 0 
Alive, n = 12 <12 2 M 5 Abdomen 2 Present 4 Positive 12 Abnormal  12 Abnormal 1 Poor 3 
12-
24 
3 F 7 Adrenal 8 Absent 8 Negative 0 Normal 0 Normal 11 Well 9 
>24 7 Thorax 1 NA 0 NA 0 NA 0 NA 0 NA 0 
Pelvis 1 
M=male, F=female, NA=not available 
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Table 3: Clinical and pathologic characteristics of neuroblastoma patients who had follow up scans at cycle 7 
Characteristic  Age at 
diagnosis 
(months) 


















<12 4 M  10 Abdomen  6 Present  8 Positive 18 Abnormal   17 Abnormal   5 Poor 9 
12-
24 
4 F  11 Adrenal  11 Absent  12 Negative  1 Normal  4 Normal  16 Well 6 
>24 13 Thorax  2 NA 1 NA 2 NA 0 NA 0 NA 6 
Pelvis  2 
Dead, n=13 <12 1 M  7 Abdomen  5 Present  6 Positive 11 Abnormal   10 Abnormal   5 Poor  7 
12-
24 
2 F  6 Adrenal  5 Absent  6 Negative  1 Normal  3 Normal  8 Well  2 
>24 10 Thorax  1 NA 1 NA 1 NA 0 NA 0 NA 4 
Pelvis  2 
Alive, n=8 <12 4 M  3 Abdomen  1 Present  2 Positive 7 Abnormal   7 Abnormal   0 Poor  2 
12-
24 
2 F  5 Adrenal  6 Absent  6 Negative  0 Normal  1 Normal  8 Well  4 
>24 2 Thorax  1 NA 0 Not 
available 
1 NA 0 NA 0 NA 2 
Pelvis  0 
M=male, F=female, NA: not available 
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Figure 1: Overall survival by cycle 4 Curie score for scores ≤ 2 vs > 2 
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Figure 3: Overall survival by relative Curie score for score ≤ 0.5 vs > 0.5 at cycle 7 
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SUPPLEMENTARY TABLES AND FIGURES 
Supplementary Table S1: Characteristics of skeletal lesions in neuroblastoma patients with 
cycle 4 scans  
  Focal Diffuse Total 




42 11 53  
Number of 
patients 




2 (1 – 9) 2.5 (1 – 5)  






42 11 53  
Number of 
patients 




3.5 (2 – 9) 2.5 (1 – 5)  
 
Supplementary Table S2: Characteristics of skeletal lesions in neuroblastoma patients with 
cycle 7 scans  
  Focal Diffuse Total 




62 14 76 
Number of 
patients 




6.5 (2 – 13) 2 (1 – 9)  






59 17 76 
Number of 
patients 








Supplementary Table S3: MIBG scan characteristics of patients who had cycle 4 scans 
Characteristic All patients, 
n=22 
Dead, n = 10 Alive, n = 12 
Baseline Curie 
score 
Median 15 Median 15 Median 14 
Range 0 - 25 Range 0 – 21 Range 0 – 25 
IQR 1.25 -
18.75 
IQR 1.25 – 
18.25 
IQR 1.5 – 
18.25 
Cycle 4 Curie 
Score 
Median 0.5 Median 0 Median 1 
Range 0 - 18 Range 0-18 Range 0-17
IQR 0 - 2 IQR - IQR 0 - 3
IQR: interquartile range 
Supplementary Table S4: MIBG scan characteristics of patients who had cycle 7 scans 
Characteristic All patients, 
n=21 
Dead, n=13 Alive, n=8 
Baseline Curie 
score 
Median 16 Median 18 Median 7.5 
Range 0 – 25 Range 0 – 25 Range 0 – 25 
IQR 2 - 22 IQR 3 – 23 IQR 1.5 – 
18.5 
Cycle 7 Curie 
Score 
Median 1 Median 2 Median 0.5 
Range 0 – 24 Range 0 – 24 Range 0 – 9 
IQR 0 - 6 IQR 0 - 6 IQR 0 - 6 
IQR: interquartile range 
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Supplementary figure 2a: Change in baseline and follow-up Curie scores and outcome for 
patients who were alive 
Supplementary figure 2b: Change in baseline and follow-up Curie scores and outcome for 






































3.1 APPENDIX I: DATABASE APPROVAL 
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3.2 APPENDIX II: ETHICS APPROVAL 
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3.3: APPENDIX III: DATA SHEETS 
Data sheet 1 
Study serial number……………………………. Date……………………………. 
Type of scan 
Unknown   ☐ Pre-treatment scan ☐ Post treatment scan ☐ 
Scoring system dividing the skeleton into 9 compartments. A 10th compartment (not shown 
will be used for soft tissue lesions. 
Schema for scoring 
0 no uptake/ no foci per segment 
1 one focal lesion per segment 
2 more than one focal lesion per segment 
3 diffuse involvement (≥50% of segment involved) 
Soft-tissue lesions will be scored as follows: 0, no mIBG 
involvement; 1, one mIBG-avid soft-tissue lesion present; 2, 
more than one mIBG-avid soft-tissue lesion present; and 3, 
mIBG avidity in a soft-tissue lesion that occupies 50% of the chest or abdomen 
*Maximum attainable score is 30
*Focal uptake: uptake with clearly defined margins
*Diffuse uptake: uptake with margins indistinguishable from background
Location/ 
segment involved 



















Upper legs/ thighs 
Lower legs/ feet 
Soft tissue 
involvement 
Lesion certainty: 0=unknown, 1=possible, 2=probable, 3=definite 
Intensity of uptake: 0 =no sites of uptake; 1= doubtful uptake; 2= obvious but mild uptake; 
3=obvious and intense uptake 
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Total number of involved body segments: 
Number of focal lesions=  Number of diffuse lesions= 
Total number of lesions on scan= 
Total Curie score=   Modified Curie score= 
Form of uptake:   
Focal ☐  Focal≥ diffuse ☐ Diffuse≥ focal☐  Diffuse ☐  




Data sheet 2 
Study serial number……………………………. Date……………………………. 
Type of scan: Pre-treatment scan ☐ 
Scoring system dividing the skeleton into 9 compartments. A 10th compartment (not shown 
will be used for soft tissue lesions. 
Schema for scoring  
0 no uptake/ no foci per segment 
1 one focal lesion per segment 
2 more than one focal lesion per segment 
3 diffuse involvement (≥50% of segment involved) 
Soft-tissue lesions will be scored as follows: 0, no mIBG 
involvement; 1, one mIBG-avid soft-tissue lesion present; 
2, more than one mIBG-avid soft-tissue lesion present; 
and 3, mIBG avidity in a soft-tissue lesion that occupies 50% of the chest or abdomen 
*Maximum attainable score is 30
*Focal uptake: uptake with clearly defined margins
*Diffuse uptake: uptake with margins indistinguishable from background
Location/ 
segment involved 



















Upper legs/ thighs 
Lower legs/ feet 
Soft tissue 
involvement 
Lesion certainty: 0=unknown, 1=possible, 2=probable, 3=definite 
Intensity of uptake: Intensity of uptake: 0 =no sites of uptake; 1= doubtful uptake; 2= obvious 
but mild uptake; 3=obvious and intense uptake 
Total number of involved body segments: 
Number of focal lesions=  Number of diffuse lesions= 
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Total number of lesions on scan= 
Total Curie score=   Modified Curie score= 
Form of uptake:  
Focal ☐  Focal≥ diffuse ☐ Diffuse≥ focal☐  Diffuse ☐  
 
MIBG Uptake in iliac crest Yes ☐  No ☐ 
 
Type of scan: Post treatment scan ☐ 
Scoring system dividing the skeleton into 9 compartments. A 10th compartment (not shown 
will be used for soft tissue lesions. 
 
Schema for scoring  
0 no uptake/ no foci per segment 
1 one focal lesion per segment 
2 more than one focal lesion per segment 
3 diffuse involvement (≥50% of segment involved) 
 
Soft-tissue lesions will be scored as follows: 0, no mIBG 
involvement; 1, one mIBG-avid soft-tissue lesion present; 
2, more than one mIBG-avid soft-tissue lesion present; 
and 3, mIBG avidity in a soft-tissue lesion that occupies 50% of the chest or abdomen 
*Maximum attainable score is 30 
*Focal uptake: uptake with clearly defined margins 










Certainty  Intensity of 
uptake 
Head       
Cervico-thoracic 
spine 
     
Ribs/ sternum/ 
scapula 
     
Lumbosacral 
spine 
     
Pelvis       
Upper arms      
Forearm and 
hands 
     
Upper legs/ thighs      
Lower legs/ feet      
Soft tissue 
involvement 
     
Lesion certainty: 0=unknown, 1=possible, 2=probable, 3=definite 
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Intensity of uptake: Intensity of uptake: 0 =no sites of uptake; 1= doubtful uptake; 2= obvious 
but mild uptake; 3=obvious and intense uptake 
Total number of involved body segments: 
Number of focal lesions=  Number of diffuse lesions= 
Total number of lesions on scan= 
Total Curie score=   Modified Curie score= 
Form of uptake:  
Focal ☐  Focal≥ diffuse ☐ Diffuse≥ focal☐  Diffuse ☐  
 





Data sheet 3 
Folder number:    Study ID:  Sex: M [  ] F [  ] 
Age/DOB:    Date of diagnosis of NB:  Stage of NB: 
Age at diagnosis: 
Race: White [   ]  Black [   ]  Mixed race [   ] 
Histopathology result available?  Yes [   ]  No [   ] 
Histopathology report: 
Catecholamine level result available? Yes [   ] No [   ] 
Urine HMA/VMA result [ ] Elevated (HMA/VMA)  Yes [  ] No[   ] 
Bone marrow (BM) at diagnosis result available?  Yes [   ]  No [   ]  
Percent (%) of marrow infiltration at diagnosis [     ] 
Any additional BM results 
Date    % BM involvement [    ] 
N-myc amplification result: 
Haematologic indices:  
Date of test: 
WCC  Hb  Platelets  LDH   Ferritin 
HIV status 
Site of primary tumor  
Cervical [  ] Thorax [  ] Abdomen [  ] Pelvis [  ] Retroperitoneum [  ]  
Unknown site [   ] 
Bone scan results: 
Chemotherapy treatment dates 
1st cycle     2nd cycle 
3rd cycle     4th cycle 
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5th cycle     6th cycle 
**Type of chemotherapy 
Did patient undergo bone marrow transplantation? Yes [   ] No [   ] 
Intervening events eg relapse, progression, death, hospitalizations, infections, anaemia/ 
haemotransfusion/ mucositis  
Intervening event?  Yes [   ]  No [   ]   
Type of event:  Number of events: 
Date of first event:  
Event free survival (time from diagnosis to first event): 
Outcome: Dead [   ] Alive [   ]  If dead, date of death: 
Cause of death: 
Disease related [   ] Treatment related [   ] death unrelated to disease or treatment [   ] 
 
Did patient have surgery Yes [   ]  No [   ]   
If yes, date of surgery: 
Outcome of surgery: Tumour completely removed [   ] Not completely removed [   ]   
Need for second line chemotherapy? Yes [   ] No [   ] 
Second line chemotherapy: 
1st cycle:     2nd cycle: 
3rd cycle:     4th cycle: 
5th cycle:     6th cycle: 
Results of other imaging (CT/MRI) at end of treatment 
Is disease still present at site of primary Yes [   ]  No [   ]    
Metastatic disease still present? Yes [   ]   No [   ]    
If yes, site(s) of disease 
Is there disease extension into neural foramina? Yes [   ]  No [   ]   
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Date of last clinic visit: 
Date of last known contact: 
Overall survival (time from diagnosis to death to death or last examination): 
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3.4: APPENDIX IV: JOURNAL OF PEDIATRIC HEMATOLOGY/ ONCOLOGY 
AUTHOR GUIDELINES 
Journal of Pediatric Hematology/Oncology 
Online Submission and Review System 
SCOPE 
Journal of Pediatric Hematology-Oncology 
reports on major advances in the diagnosis 
and treatment of cancer and blood diseases in 
children. Each issue presents informative 
case studies and original research articles 
from leading clinicians and investigators 
worldwide. 






A submitted manuscript must be an original contribution not previously published (except as 
an abstract or a preliminary report), must not be under consideration for publication 
elsewhere, and, if accepted, must not be published elsewhere in similar form, in any 
language, without the consent of Lippincott Williams & Wilkins. Each person listed as an 
author is expected to have participated in the study to a significant extent. Although the 
editors and referees make every effort to ensure the validity of published manuscripts, the 
final responsibility rests with the authors, not with the Journal, its editors, or the publisher. 
All manuscripts must be submitted on-line through the journal's Web site at 
https://jpho.edmgr.com/. See submission instructions under “On-line manuscript 
submission.” 
Patient Anonymity and Informed Consent: It is the author's responsibility to ensure that a 
patient's anonymity be carefully protected and to verify that any experimental investigation 
with human subjects reported in the manuscript was performed with informed consent and 
following all the guidelines for experimental investigation with human subjects required by 
the institution(s) with which all the authors are affiliated. Authors should mask patients' eyes 
and remove patients' names from figures. Photographs with bars placed over the eyes of 
patients CANNOT be used in publication, unless they obtain written consent from the 
patients and submit written consent with the manuscript. 
Conflicts of interest 
Authors must state all possible conflicts of interest in the manuscript, including financial, 
consultant, institutional and other relationships that might lead to bias or a conflict of interest. 
If there is no conflict of interest, this should also be explicitly stated as none declared. All 
sources of funding should be acknowledged in the manuscript. All relevant conflicts of 
interest and sources of funding should be included on the title page of the manuscript with the 
heading “Conflicts of Interest and Source of Funding:”. For example: 
Conflicts of Interest and Source of Funding: A has received honoraria from Company Z. B is 
currently receiving a grant (#12345) from Organization Y, and is on the speaker’s bureau for 
Organization X – the CME organizers for Company A. For the remaining authors none were 
declared. 
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In addition, each author must complete and submit the journal's copyright transfer agreement, 
which includes a section on the disclosure of potential conflicts of interest based on the 
recommendations of the International Committee of Medical Journal Editors, "Uniform 
Requirements for Manuscripts Submitted to Biomedical Journals" 
(www.icmje.org/update.html). 
A copy of the form is made available to the submitting author within the Editorial Manager 
submission process. Co-authors will automatically receive an Email with instructions on 
completing the form upon submission. 
Compliance with NIH and Other Research Funding Agency Accessibility 
Requirements: A number of research funding agencies now require or request authors to 
submit the post-print (the article after peer review and acceptance but not the final published 
article) to a repository that is accessible online by all without charge. As a service to our 
authors, LWW will identify to the National Library of Medicine (NLM) articles that require 
deposit and will transmit the post-print of an article based on research funded in whole or in 
part by the National Institutes of Health, Wellcome Trust, Howard Hughes Medical Institute, 
or other funding agencies to PubMed Central. The revised Copyright Transfer Agreement 
provides the mechanism. 
Permissions: Authors must submit written permission from the copyright owner (usually the 
publisher) to use direct quotations, tables, or illustrations that have appeared in copyrighted 
form elsewhere, along with complete details about the source. Any permissions fees that 
might be required by the copyright owner are the responsibility of the authors requesting use 
of the borrowed material, not the responsibility of Lippincott Williams & Wilkins. 
MANUSCRIPT SUBMISSION 
On-Line Manuscript Submission: All manuscripts must be submitted on-line through the 
new Web site at https://jpho.edmgr.com/. 
First-time users: Please click the Register button from the main top menu and enter the 
requested information. On successful registration, you will be sent an e-mail indicating your 
user name and password. Print a copy of this information for future reference. Note: If you 
have received an e-mail from us with an assigned user ID and password, or if you are a repeat 
user, do not register again. Just log in. Once you have an assigned ID and password, you do 
not have to re-register, even if your status changes (that is, author, reviewer, or editor). 
Authors: Please click the login button from the menu at the top of the page and log in to the 
system as an Author. Submit your manuscript according to the author instructions. You will 
be able to track the progress of your manuscript through the system. If you experience 
difficulties using the system, please contact JPHO@ymail.com. Requests for help and other 
questions will be addressed in the order received. 
Preparation of Manuscript: Manuscripts that do not adhere to the following instructions 
will be returned to the corresponding author for technical revision before undergoing peer 
review. 
Title Page: Include on the title page (a) complete manuscript title; (b) authors' full names, 
highest academic degrees, and affiliations; (c) name and address for correspondence, 
including fax number, telephone number, and e-mail address; (d) address for reprints if 
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different from that of corresponding author; and (e) all sources of support, including 
pharmaceutical and industry support, that require acknowledgment. 
The title page must also include disclosure of funding received for this work from any of the 
following organizations: National Institutes of Health (NIH); Wellcome Trust; Howard 
Hughes Medical Institute (HHMI); and other(s). 
Unstructured Abstract and Key Words: Limit the abstract to 200 words. It must be factual 
and comprehensive. Limit the use of abbreviations and acronyms, and avoid general 
statements (eg, “the significance of the results is discussed”). List three to five key words or 
phrases. 
Text: Organize the manuscript into four main headings: Introduction, Materials and Methods, 
Results, and Discussion. Define abbreviations at first mention in text and in each table and 
figure. If a brand name is cited, supply the manufacturer's name and address (city and 
state/country). All forms of support, including pharmaceutical industry support, must be 
acknowledged in the Acknowledgment section. 
Abbreviations: For a list of standard abbreviations, consult the Council of Biology Editors 
Style Guide (available from the Council of Science Editors, 9650 Rockville Pike, Bethesda, 
MD 20814) or other standard sources. Write out the full term for each abbreviation at its first 
use unless it is a standard unit of measure. 
References: The authors are responsible for the accuracy of the references. Key the 
references (double-spaced) at the end of the manuscript. Cite the references in text in the 
order of appearance. Cite unpublished data—such as papers submitted but not yet accepted 
for publication and personal communications, including e-mail communications—in 
parentheses in the text. If there are more than three authors, name only the first three authors 
and then use et al. Refer to the List of Journals Indexed in Index Medicus for abbreviations of 
journal names, or access the list at http://www.nlm.nih.gov/tsd/serials/lji.html. Sample 
references are given below: 
Journal Article 
1. Ang KK, Price RE, Stephens LC, et al. The tolerance of primate spinal cord to re-
irradiation. Int J Radiat Oncol Biol Phys. 1993;25:459–464.
Book Chapter 
2. Dimery IW. Chemotherapy in head and neck cancer. In: Myerhoff WI, Rice DH, eds.
Otolaryngology: head and neck surgery, 2nd ed. Philadelphia: WB Saunders, 1992:1027–
1045.
Entire Book 
3. Virchow R. Cellular Pathology. Philadelphia: JB Lippincott, 1863.
Software 
4. Epi Info [computer program]. Version 6. Atlanta, GA: Centers for Disease Control and
Prevention; 1994.
Online Journals 
5. Friedman SA. Preeclampsia: a review of the role of prostaglandins. Obstet Gynecol [serial
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online]. January 1988;71:22–37. Available from: BRS Information Technologies, McLean, 
VA. Accessed December 15, 1990. 
Database 
6. CANCERNET-PDQ [database online]. Bethesda, MD: National Cancer Institute; 1996.
Updated March 29, 1996.
World Wide Web 
7. Gostin LO. Drug use and HIV/AIDS [JAMA HIV/AIDS Web site]. June 1, 1996. Available
at: http://www.ama-assn.org/special/hiv/ethics. Accessed June 26, 1997.
URL (Uniform Resource Locator) 
8. (J. M. Kramer, K. Kramer [jmkramer@umich.edu], e-mail, March 6, 1996).
Figures: 
A) Creating Digital Artwork
1. Learn about the publication requirements for Digital Artwork:
http://links.lww.com/ES/A42
2. Create, Scan and Save your artwork and compare your final figure to the Digital
Artwork Guideline Checklist (below).
3. Upload each figure to Editorial Manager in conjunction with your manuscript text and
tables.
B) Digital Artwork Guideline Checklist
Here are the basics to have in place before submitting your digital artwork:
 Artwork should be saved as TIFF, EPS, or MS Office (DOC, PPT, XLS) files. High
resolution PDF files are also acceptable.
 Crop out any white or black space surrounding the image.
 Diagrams, drawings, graphs, and other line art must be vector or saved at a resolution
of at least 1200 dpi. If created in an MS Office program, send the native (DOC, PPT,
XLS) file.
 Photographs, radiographs and other halftone images must be saved at a resolution of
at least 300 dpi.
 Photographs and radiographs with text must be saved as postscript or at a resolution
of at least 600 dpi.
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 Each figure must be saved and submitted as a separate file. Figures should not be
embedded in the manuscript text file.
Remember: 
 Cite figures consecutively in your manuscript.
 Number figures in the figure legend in the order in which they are discussed.
 Upload figures consecutively to the Editorial Manager web site and enter figure
numbers consecutively in the Description field when uploading the files.
Figure Legends: Include legends for all figures. They should be brief and specific, and they 
should appear on a separate manuscript page after the references. Use scale markers in the 
image for electron micrographs, and indicate the type of stain used. 
Color Figures: The journal accepts for publication color figures that will enhance an article. 
Authors who submit color figures will receive an estimate of the cost for color reproduction. 
If they decide not to pay for color reproduction, they can request that the figures be converted 
to black and white at no charge. 
Tables: Create tables using the table creating and editing feature of your word processing 
software (e.g., Word, WordPerfect). Do not use Excel or comparable spreadsheet programs. 
Group all tables in a separate file. Cite tables consecutively in the text, and number them in 
that order. Each table should appear on a separate sheet and should include the table title, 
appropriate column heads, and explanatory legends (including definitions of any 
abbreviations used). Do not embed tables within the body of the manuscript. They should be 
self-explanatory and should supplement, rather than duplicate, the material in the text. 
Supplemental Digital Content 
Supplemental Digital Content (SDC): Authors may submit SDC via Editorial Manager to 
LWW journals that enhance their article's text to be considered for online posting. SDC may 
include standard media such as text documents, graphs, audio, video, etc. On the Attach Files 
page of the submission process, please select Supplemental Audio, Video, or Data for your 
uploaded file as the Submission Item. If an article with SDC is accepted, our production staff 
will create a URL with the SDC file. The URL will be placed in the call-out within the 
article. SDC files are not copy-edited by LWW staff, they will be presented digitally as 
submitted. For a list of all available file types and detailed instructions, please visit 
http://links.lww.com/A142. 
SDC Call-outs 
Supplemental Digital Content must be cited consecutively in the text of the submitted 
manuscript. Citations should include the type of material submitted (Audio, Figure, Table, 
etc.), be clearly labeled as "Supplemental Digital Content," include the sequential list 
number, and provide a description of the supplemental content. All descriptive text should be 




We performed many tests on the degrees of flexibility in the elbow (see Video, Supplemental 
Digital Content 1, which demonstrates elbow flexibility) and found our results inconclusive.  
List of Supplemental Digital Content 
A listing of Supplemental Digital Content must be submitted at the end of the manuscript file. 
Include the SDC number and file type of the Supplemental Digital Content. This text will be 
removed by our production staff and not be published. 
Example: 
Supplemental Digital Content 1. wmv  
SDC File Requirements 
All acceptable file types are permissible up to 10 MBs. For audio or video files greater than 
10 MBs, authors should first query the journal office for approval. For a list of all available 
file types and detailed instructions, please visit http://links.lww.com/A142.  
Style: In general, style should be patterned after the American Medical Association Manual 
of Style (9th edition). Stedman's Medical Dictionary (27th edition) and Merriam Webster's 
Collegiate Dictionary (10th edition) should be used as standard references. Drugs and 
therapeutic agents should be referred to by their accepted generic or chemical names. The 
name should not be abbreviated. Code numbers should be used only when a generic name is 
not yet available. In that case, the chemical name and a figure giving the chemical structure 
of the drug is required. Copyright or trade names of drugs should be capitalized and placed in 
parentheses after the name of the drug. Names and locations (city and state in USA; city and 
country outside USA) of manufacturers of drugs, supplies, or equipment cited in a manuscript 
are required to comply with trademark law and should be provided in parentheses. Units of 
measure should be expressed in the metric system, and temperatures should be expressed in 
degrees Celsius. Conventional units should be written as SI units as appropriate. 
CLINICAL AND LABORATORY OBSERVATIONS: Clinical observations may include 
case histories that demonstrate novel findings or associations, important clinical responses 
when a larger study is not needed to address a specific issue, or a unique laboratory 
observation linked to clinical care and/or practice. Text should contain 2500 words or fewer, 
with a brief abstract of 100 words or fewer. Abstracts outline background, observation(s), and 
conclusions. Include 4 illustrations and/or tables or fewer and 20 references or fewer. 
MEDICAL PROGRESS: Review articles for this section should highlight what is 
particularly new and novel in a field related to pediatric hematology/oncology. Text should 
contain 5000 words or fewer and 100 references or fewer. Shorter reviews are encouraged 
and preferred. Authors considering submission should consult the Editor-in-Chief. 
MORPHOLOGY CORNER: This section features photographs of especially interesting 
blood smears, bone marrow, or other tissue specimens that highlight an important aspect of 
hematology/oncology. Include an introduction of 200 words or fewer, the figure(s), a 
conclusion of 200 words or fewer, and 6 references or fewer. 
RADIOLOGY CORNER: This section features photographs of scans of radiographic 
studies, such as plain radiographs, bone scans, computed tomography scans, magnetic 
resonance images, or other modalities highlighting a special feature of a topic or case. Include 
an introduction of 200 words or fewer, the figure(s), a conclusion of 200 words or fewer, and 
6 references or fewer. 
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HISTORICAL INSIGHTS: Historical insights include concise descriptions or analyses of 
historical importance in the field of pediatric hematology/oncology. These may include 
personal descriptions of historical figures, important papers, and interesting occurrences that 
led to advancements in pediatric hematology/oncology. Photographs and artwork are 
welcome. Text should contain 2500 words or fewer and include 25 references or fewer. All 
material should be original or carry permission for publication. 
LETTERS TO THE EDITOR: Letters to the editor should pertain to articles published 
within the Journal of Pediatric Hematology/Oncology or highlight important new clinical or 
laboratory insights. Text should contain 500 words or fewer. 
BOOK REVIEWS: Reviews of books should relate to topics relevant to pediatric 
hematology/oncology, including immunology and transplantation. Text should contain 1000 
words or fewer. 
ANNOUNCEMENTS: Announcements should be submitted 6 months in advance of the 
event date and may include scheduled meetings, symposia, postgraduate courses, and other 
announcements of interest to specialists in pediatric hematology/oncology. 
C o p y r i g h t / D i s c l a i m e r  N o t i c e  •  P r i v a c y  P o l i c y
